Clinical trials: Recurrent Adenocarcinoma
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
This phase II trial is studying how well triapine works as first-line or second-line therapy in treating patients with locally advanced or metastatic adenocarcinoma (cancer) of the pancreas.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT00085371
- Testing
- triapine
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
This phase II trial is studying how well tandutinib works in treating patients who have undergone surgery for metastatic kidney cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00408902
- Testing
- tandutinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
Randomized phase III trial to compare the effectiveness of irinotecan with that of combination chemotherapy in treating patients who have advanced colorectal cancer that has not responded to previous treatment.
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00005036
- Testing
- irinotecan hydrochloride, oxaliplatin, leucovorin calcium
- Where
- United States
- Volunteers
- 560 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002711
- Testing
- chemotherapy, cisplatin, paclitaxel
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastric or Gastroesophageal Junction Adenocarcinoma
A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma
This is a randomized, multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 in combination with…
- Trial name
- NCT02340975
- Testing
- MEDI4736 + tremelimumab, MEDI4736, Tremelimumab
- Where
- 28 sites in United States, Canada and 4 more
- Volunteers
- 114 people
- Sponsor
- MedImmune LLC
Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder
S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma
This phase II trial is studying how well sorafenib works in treating patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma.
- Conditions
- Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder, Cholangiocarcinoma of the Extrahepatic Bile Duct
- Trial name
- NCT00238212
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
This trial studies how well 68Ga-PSMA-11 PET scan works in imaging patients with prostate cancer. Diagnostic procedures, such as 68Ga-PSMA-11 PET may find and diagnose prostate cancer and improve monitoring of treatment response.
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8
- Trial name
- NCT04777071
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- University of Washington
Lung Adenocarcinoma, Lung Cancer
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
The purpose of this study is to determine the safety, tolerability and overall response rate of trametinib when given in combination with erlotinib in patients with Stage IV or recurrent lung adenocarcinoma that cannot be treated…
- Conditions
- Lung Adenocarcinoma, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV
- Trial name
- NCT03076164
- Testing
- Trametinib, Erlotinib
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophageal Cancer, Gastric Cancer
Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00397904
- Testing
- cetuximab, cisplatin, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
RATIONALE: Thalidomide may stop the growth of neuroendocrine tumors by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have metastatic neuroendocrine…
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome
- Trial name
- NCT00027638
- Testing
- thalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma
Study on Recurrence Monitoring of Hepatocellular Carcinoma With 5-Hydroxymethylcytosine Test
In this study, investigators aim to find out how plasma 5hmC level changes in hepatocellular carcinoma patients after liver resection, and determine whether 5hmC can be used as a biomarker for HCC recurrence monitoring.
- Trial name
- NCT03493763
- Testing
- 5hmC profile in plasma cell-free DNA after liver resection
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Zhongshan Hospital
Intrahepatic Cholangiocarcinoma (Icc)
Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study
This multicenter real-world study assesses the efficacy and safety of adjuvant therapies in postoperative intrahepatic cholangiocarcinoma (ICC) patients with high-risk recurrence factors.
- Trial name
- NCT07640048
- Testing
- Adebrelimab, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Peking Union Medical College Hospital
Hepatocellular Carcinoma, Liver Cirrhosis
Study of Factors Predicting Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma (HCC)
Results of liver transplantation, the best theoretical treatment for HCC, are limited by tumor recurrence. In order to limit this risk Milan criteria was proposed in 1996.
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Evidence of Liver Transplantation
- Trial name
- EFAPRE (NCT01198704)
- Testing
- search of factors predicting tumor recurrence
- Where
- France
- Volunteers
- 372 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Prostate Cancer
ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of prostate cancer.
- Trial name
- NCT00025116
- Testing
- gefitinib
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- NCIC Clinical Trials Group
Recurrent Pancreatic Ductal Adenocarcinoma
Additional Treatment for Isolated Local Pancreatic Cancer Recurrence Using Stereotactic Body Radiation Therapy
A randomized controlled trial, nested within an existing prospective cohort (Dutch Pancreatic Cancer Project; PACAP) according to the 'trials within cohorts' (TwiCs) design in which the effect of additional local ablative therapy…
- Trial name
- ARCADE (NCT04881487)
- Testing
- Additional stereotactic body radiation therapy
- Where
- 3 sites in Netherlands
- Volunteers
- 174 people
- Sponsor
- UMC Utrecht
Lung Cancer
Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as vinorelbine, gemcitabine, docetaxel, paclitaxel, and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00079287
- Testing
- carboplatin, docetaxel, gemcitabine hydrochloride
- Where
- 24 sites in Japan
- Sponsor
- Japan Multinational Trial Organization
Liver Cancer
Sho-Saiko-To Following Removal of Liver Cancer By Embolization in Treating Patients With Liver Cancer That Cannot Be Surgically Removed
RATIONALE: The Chinese herbal medicine Sho-saiko-to contains ingredients that may slow the growth of tumor cells and stimulate a person's immune system to help kill tumor cells.
- Trial name
- NCT00040898
- Testing
- Sho-saiko-to
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colon Cancer, Colon Adenocarcinoma
Survival Outcomes by Tumor-Node Stage and Recurrence Patterns in Colon Cancer After Radical Surgery
Colon cancer is one of the most common cancers worldwide, and even after curative (radical) surgery, some patients develop recurrence or distant metastasis.
- Conditions
- Colon Cancer, Colon Adenocarcinoma, Colon Cancer Stage III, Colon Cancer Stage I
- Trial name
- STARS (NCT07167147)
- Where
- Taiwan
- Volunteers
- 7,259 people
- Sponsor
- Chang Gung Memorial Hospital
Prostate Cancer
Atrasentan in Treating Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase III trial to determine the effectiveness of atrasentan in treating patients who have prostate…
- Trial name
- NCT00046943
- Testing
- atrasentan hydrochloride
- Where
- United States
- Sponsor
- Abbott
Advanced Solid Tumors, Breast Cancer Recurrent
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
The goal of this study is to identify a safe and tolerated dose of the orally administered DHX9 inhibitor ATX-559. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of…
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer
- Trial name
- NCT06625515
- Testing
- ATX-559
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Accent Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.